Cerveau Technologies
Dave Casebier was formerly VP of CMC forNavidea Biopharmaceuticals, working on the successful US and EU approval of Lymphoseek and the implementation of commercial supply chain and development of Flutafuranol, NAV4694 and Senior VP at Tokai Pharmaceuticals, responsible for CMC. He was also the Senior Director at BMSMI-Lantheus Medical Imaging, program leader, discovery and development of Flurpiridaz and LMI1195 and the VP at ArQule Inc, responsible for foundational technology and creation of the Production and Engineering groups.
This person is not in any offices
Cerveau Technologies
Cerveau Technologies focused on providing information and technologies to researchers and clinicians to improve brain health.